WO2024103579A1 - Procédé de préparation de particule de pseudovirus de coronavirus - Google Patents
Procédé de préparation de particule de pseudovirus de coronavirus Download PDFInfo
- Publication number
- WO2024103579A1 WO2024103579A1 PCT/CN2023/081026 CN2023081026W WO2024103579A1 WO 2024103579 A1 WO2024103579 A1 WO 2024103579A1 CN 2023081026 W CN2023081026 W CN 2023081026W WO 2024103579 A1 WO2024103579 A1 WO 2024103579A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasmid
- preparation
- protein
- coronavirus
- gene
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 32
- 241001112090 Pseudovirus Species 0.000 title claims abstract description 18
- 239000013612 plasmid Substances 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 239000013598 vector Substances 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 12
- 230000001177 retroviral effect Effects 0.000 claims abstract description 11
- 238000001514 detection method Methods 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 238000001890 transfection Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000003908 quality control method Methods 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 5
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 5
- 101150104269 RT gene Proteins 0.000 claims description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 5
- 101150062334 int gene Proteins 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims description 4
- 238000001476 gene delivery Methods 0.000 claims description 4
- -1 i.e. Substances 0.000 claims description 3
- 101100545272 Caenorhabditis elegans zif-1 gene Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 abstract description 11
- 230000028993 immune response Effects 0.000 abstract description 7
- 229940096437 Protein S Drugs 0.000 abstract description 5
- 101710198474 Spike protein Proteins 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 17
- 241000700605 Viruses Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 102100031673 Corneodesmosin Human genes 0.000 description 4
- 101710139375 Corneodesmosin Proteins 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229940022962 COVID-19 vaccine Drugs 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 2
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 2
- 102100034353 Integrase Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229940126580 vector vaccine Drugs 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 108091007576 SARS-CoV-2 structural proteins Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010028403 hemagglutinin esterase Proteins 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un procédé de préparation d'une particule de pseudovirus de coronavirus. En construisant un plasmide (1) : un vecteur rétroviral éliminant les gènes RT et INT, dans lequel une séquence génétique d'une protéine NC du vecteur rétroviral est remplacée par une séquence génétique d'une protéine N d'un coronavirus ; et un plasmide (2) : un plasmide exprimant une protéine de spicule du coronavirus et une séquence marqueur, la particule de pseudovirus du coronavirus est préparée. La particule de pseudovirus préparée selon le procédé de préparation peut charger efficacement l'ARN, renforçant ainsi la réponse immunitaire à la protéine de spicule SARS-CoV-2-Spike chez la souris, améliorant la production d'anticorps et présentant de très bonnes perspectives d'application clinique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211443414.2A CN116024269B (zh) | 2022-11-18 | 2022-11-18 | 一种冠状病毒假病毒颗粒的制备方法 |
| CN202211443414.2 | 2022-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024103579A1 true WO2024103579A1 (fr) | 2024-05-23 |
Family
ID=86072992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/081026 WO2024103579A1 (fr) | 2022-11-18 | 2023-03-13 | Procédé de préparation de particule de pseudovirus de coronavirus |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116024269B (fr) |
| WO (1) | WO2024103579A1 (fr) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1576143A2 (fr) * | 2002-05-17 | 2005-09-21 | Emory University | Particules pseudovirales, procede de fabrication et compositions immunogeniques |
| US20100297168A1 (en) * | 2007-08-03 | 2010-11-25 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| CN112375768A (zh) * | 2020-11-16 | 2021-02-19 | 同济大学 | Covid-19冠状病毒的假病毒及其制备方法和应用 |
| CN113881642A (zh) * | 2021-07-21 | 2022-01-04 | 上海市食品药品检验研究院 | 一种新型冠状病毒假病毒及其构建方法和应用 |
| WO2022057540A1 (fr) * | 2020-09-21 | 2022-03-24 | 上海交通大学 | Vaccin contre le sars-cov-2 à base de modification de revêtement lentiviral et de distribution d'arnm et procédé de préparation s'y rapportant |
| CN114350711A (zh) * | 2021-12-23 | 2022-04-15 | 复百澳(苏州)生物医药科技有限公司 | 病毒样颗粒及其构建方法和应用 |
| US20220119776A1 (en) * | 2020-10-20 | 2022-04-21 | George Mason Research Foundation, Inc. | Hybrid alphavirus-sars-cov-2 particle and methodology of making and using same |
| WO2022191801A2 (fr) * | 2021-03-10 | 2022-09-15 | Sanlioglu Salih | Vaccin contre la covid-19 à base d'intégrase du vih défectueux à médiation par un lentivirus de nouvelle génération codant pour la protéine de spicule du sars-cov-2 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022014808A2 (pt) * | 2020-01-31 | 2022-09-20 | Beth Israel Deaconess Medical Ct Inc | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 |
| CN111893097A (zh) * | 2020-06-16 | 2020-11-06 | 惠君生物医药科技(杭州)有限公司 | 一种冠状病毒假病毒包装系统及一步法包装方法 |
| WO2022235678A1 (fr) * | 2021-05-03 | 2022-11-10 | Ohio State Innovation Foundation | Vaccins peptidiques anti-coronavirus humains et leurs procédés d'utilisation |
-
2022
- 2022-11-18 CN CN202211443414.2A patent/CN116024269B/zh active Active
-
2023
- 2023-03-13 WO PCT/CN2023/081026 patent/WO2024103579A1/fr unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1576143A2 (fr) * | 2002-05-17 | 2005-09-21 | Emory University | Particules pseudovirales, procede de fabrication et compositions immunogeniques |
| US20100297168A1 (en) * | 2007-08-03 | 2010-11-25 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| CN102083462A (zh) * | 2007-08-03 | 2011-06-01 | 巴斯德研究院 | 慢病毒基因转移载体及其医学应用 |
| WO2022057540A1 (fr) * | 2020-09-21 | 2022-03-24 | 上海交通大学 | Vaccin contre le sars-cov-2 à base de modification de revêtement lentiviral et de distribution d'arnm et procédé de préparation s'y rapportant |
| US20220119776A1 (en) * | 2020-10-20 | 2022-04-21 | George Mason Research Foundation, Inc. | Hybrid alphavirus-sars-cov-2 particle and methodology of making and using same |
| CN112375768A (zh) * | 2020-11-16 | 2021-02-19 | 同济大学 | Covid-19冠状病毒的假病毒及其制备方法和应用 |
| WO2022191801A2 (fr) * | 2021-03-10 | 2022-09-15 | Sanlioglu Salih | Vaccin contre la covid-19 à base d'intégrase du vih défectueux à médiation par un lentivirus de nouvelle génération codant pour la protéine de spicule du sars-cov-2 |
| CN113881642A (zh) * | 2021-07-21 | 2022-01-04 | 上海市食品药品检验研究院 | 一种新型冠状病毒假病毒及其构建方法和应用 |
| CN114350711A (zh) * | 2021-12-23 | 2022-04-15 | 复百澳(苏州)生物医药科技有限公司 | 病毒样颗粒及其构建方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116024269A (zh) | 2023-04-28 |
| CN116024269B (zh) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| WO2021254327A1 (fr) | Vaccin à vecteur viral de type à remplacement d'enveloppe et procédé de construction associé | |
| CN112618707B (zh) | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 | |
| WO2012053646A1 (fr) | Vecteur de virus pour des vaccins amorce/rappel, qui comprend un vecteur de virus de la vaccine et un vecteur de virus de sendai | |
| CN113151184B (zh) | 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法 | |
| CN112386684A (zh) | 一种covid-19疫苗及其制备方法和应用 | |
| CN107267469B (zh) | 纤毛蛋白嵌合型重组人b型腺病毒及其制备方法 | |
| CN113666990A (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| US20140004146A1 (en) | Method for producing virus-like particle by using drosophila cell and applications thereof | |
| CN112552413B (zh) | 新型冠状病毒重组蛋白亚单位疫苗 | |
| WO2023051701A1 (fr) | Arnm, protéine et vaccin contre l'infection par sars-cov-2 | |
| Valley-Omar et al. | Abrogation of contaminating RNA activity in HIV-1 Gag VLPs | |
| JPH01500161A (ja) | Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン | |
| CN114507675A (zh) | 一种新型冠状病毒mRNA疫苗及其制备方法 | |
| CN112641937B (zh) | 一种重组腺病毒在制备预防病毒的药物中的用途 | |
| CN113398259A (zh) | 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用 | |
| WO2024103579A1 (fr) | Procédé de préparation de particule de pseudovirus de coronavirus | |
| CN116426543B (zh) | 一种新型冠状病毒疫苗及其制备方法 | |
| WO2021179351A1 (fr) | Combinaison immunitaire pour induire un anticorps neutralisant à large spectre contre le vih-1 | |
| CN110229219B (zh) | 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途 | |
| Olivero-Deibe et al. | Expression, purification, and characterization of bovine leukemia virus-like particles produced in drosophila S2 cells | |
| WO2021036247A1 (fr) | Lymphocyte t exprimant un récepteur chimérique à l'antigène ciblant her2 et interférant avec l'expression de l'il-6, procédé de préparation et utilisation | |
| CN108743934B (zh) | 利用重组水泡性口炎病毒构建预防猪流行性腹泻病毒疫苗 | |
| WO2021211535A1 (fr) | Compositions de vaccins contre les coronavirus et procédés d'utilisation | |
| KR20230008707A (ko) | 코로나바이러스 치료용 백신 조성물 |